2.94
Precigen Inc stock is traded at $2.94, with a volume of 172.87M.
It is up +58.92% in the last 24 hours and up +58.92% over the past month.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
See More
Previous Close:
$1.85
Open:
$2.6
24h Volume:
172.87M
Relative Volume:
35.00
Market Cap:
$867.83M
Revenue:
$6.23M
Net Income/Loss:
$-95.90M
P/E Ratio:
-7.5385
EPS:
-0.39
Net Cash Flow:
$-68.47M
1W Performance:
+65.17%
1M Performance:
+58.92%
6M Performance:
+50.00%
1Y Performance:
+174.77%
Precigen Inc Stock (PGEN) Company Profile
Name
Precigen Inc
Sector
Industry
Phone
301-556-9900
Address
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Compare PGEN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
PGEN
Precigen Inc
|
2.94 | 551.25M | 6.23M | -95.90M | -68.47M | -0.39 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-22-24 | Downgrade | JP Morgan | Neutral → Underweight |
May-23-23 | Initiated | JP Morgan | Neutral |
Nov-18-22 | Initiated | Cantor Fitzgerald | Overweight |
Feb-25-21 | Initiated | Stifel | Buy |
Feb-22-21 | Initiated | Wells Fargo | Overweight |
Feb-18-21 | Initiated | B. Riley Securities | Buy |
May-08-20 | Initiated | H.C. Wainwright | Buy |
View All
Precigen Inc Stock (PGEN) Latest News
Precigen’s Papzimeous Approval Allows US FDA CBER Director To Emphasize Flexibility - insights.citeline.com
Precigen, Inc. Stock (PGEN) Opinions on FDA Approval of Papzimeos - Quiver Quantitative
FDA Grants Full Approval to Precigen’s Papzimeos for Recurrent Respiratory Papillomatosis - PharmExec
Precigen shares jump after US FDA approves first therapy for rare respiratory disease - Reuters
Precigen stock soars after FDA approves first RRP treatment - Investing.com
A speedy FDA approval for Precigen’s rare disease gene therapy - BioWorld MedTech
Evolv Technologies, Precigen, Hesai Group And Other Big Stocks Moving Higher On Friday - Benzinga
Precigen’s Remarkable Uptick: What Drives It? - StocksToTrade
US FDA approves Precigen's immunotherapy for rare respiratory disease - Reuters
Why Is Precigen Stock Surging On Friday? - inkl
Precigen Wins First FDA Immunotherapy Nod for Recurrent Respiratory Papillomatosis - BioSpace
Precigen, Twilio, Hims & Hers - TradingView
Precigen Shares on the Rise: Is Now the Time to Invest? - timothysykes.com
Precigen scores FDA nod for first-ever treatment for HPV-related disorder - Fierce Pharma
Precigen Stock (PGEN) Roars Over 60% Higher on FDA Green Light for Papzimeos Therapy - TipRanks
Precigen Stock Shot Through The Roof On Friday Morning – Here’s Why - Stocktwits
Precigen announces full FDA approval of Papzimeos - MarketScreener
Precigen stock surges on FDA approval (update) (PGEN:NASDAQ) - Seeking Alpha
Precigen wins immunotherapy approval; Pfizer sickle cell drug fails trial - Yahoo Finance
Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis - PR Newswire
FDA clears Precigen's rare tumour immunotherapy - pharmaphorum
Is Precigen Inc. exposed to political riskJuly 2025 Macro Moves & Smart Investment Allocation Insights - thegnnews.com
Precigen earnings missed, revenue topped estimates - Investing.com
Precigen earnings missed, revenue topped estimates By Investing.com - Investing.com Canada
Precigen 2025 Q2 Earnings Significant Net Loss Reduction - AInvest
Precigen (PGEN) Analyst Rating Reiterated by HC Wainwright & Co. - GuruFocus
Precigen, Inc. Reports Q2 2025 Earnings and Strategic Focus - TipRanks
Quant Funds Rotate Into Precigen Inc. StockMarket Surge Signal for Swing Traders Triggered - beatles.ru
Layoff Tracker: Bicycle, Tune, Iovance, Precision Downsize to Conserve Cash - BioSpace
Precigen Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
What is the risk reward ratio of investing in Precigen Inc. stockRobust investment performance - Jammu Links News
Is it the right time to buy Precigen Inc. stockAchieve breakthrough results with expert guidance - Jammu Links News
What drives Precigen Inc. stock priceNavigate market volatility with smart strategies - Jammu Links News
When is Precigen Inc. stock expected to show significant growthPhenomenal returns - Jammu Links News
How does Precigen Inc. generate profit in a changing economyInvest in stocks with long-term growth potential - Jammu Links News
How volatile is Precigen Inc. stock compared to the marketAchieve rapid wealth accumulation with smart picks - Jammu Links News
What is the dividend policy of Precigen Inc. stockInvest smarter with comprehensive market analysis - Jammu Links News
Precigen Inc. Stock Analysis and ForecastInvest in stocks with long-term growth potential - Jammu Links News
How strong is Precigen Inc. company’s balance sheetInvest confidently with professional advice - Jammu Links News
How does Precigen Inc. compare to its industry peersSuperior trading gains - Jammu Links News
Should I hold or sell Precigen Inc. stock in 2025Remarkable growth - Jammu Links News
What catalysts could drive Precigen Inc. stock higher in 2025Grow your wealth with proven stock picks - Jammu Links News
Is Precigen Inc. a growth stock or a value stockHigh-profit stock alerts - Jammu Links News
Ranking Precigen Inc. among high performing stocks via toolsNews Based Entry Opportunity Alerts Detected - metal.it
Precigen Inc. Stock Seesawing Amid Market Uncertainty - timothysykes.com
Can Precigen Stock Continue Its Rollercoaster? - StocksToTrade
Is Precigen Inc. a Top Dividend Stock to Watch in 2025Smart Trade Plans With Risk Protection Explained - metal.it
Intraday Charts Show Spike in Precigen Inc. ActivityMulti-Bagger Potential Stock Forecast Tools Released - metal.it
What are Precigen Inc. company’s key revenue driversCapitalize on fast-moving stock trends - Jammu Links News
What are the technical indicators suggesting about Precigen Inc.Invest confidently with professional market insights - Jammu Links News
Precigen Inc Stock (PGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):